INNT News and Press, Innovate Biopharmaceuticals Inc. From 08/08/19

Innovate Biopharmaceuticals (NASDAQ: INNT ): Q2 GAAP EPS of -$0.13 in-line. More news on: Innovate Biopharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Company is exploring potential strategic opportunities and non-dilutive sources of capital, and partnerships Continued activities of the first Phase 3 clinical trial for celiac disease including the screening and monitoring of potential subjects RALEIGH, N.C., Aug. 08, 2019 (GLOBE N...

Innovate undertakes succession planning for a chief executive officer Finance team strengthened and well positioned for future growth Second quarter earnings release expected August 8, 2019 RALEIGH, N.C., July 15, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasd...

RALEIGH, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment of Ed Sitar as its Chief Financial Off...

RALEIGH, N.C., June 10, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced the start of the first phase 3 clinical trial in celiac dise...

Introduction Every year the Russell Indexes are rebalanced to bring in new stocks and remove underperforming stocks. The FTSE Russell calls this event the annual reconstitution process, and it begins with evaluations in May and moves to the selection process on June 7th with the newly recons...

BioCryst Pharmaceuticals BCRX  -47%  on underwhelming Phase 3 results for BCX7353. More news on: China Bat Group, Inc., Innovate Biopharmaceuticals, Inc., Stocks on the move, Read more ...

Analyst Meeting to be held at 4:30pm ET today to discuss NASH data and provide clinical updates Three posters presented at DDW 2019 highlighted the protective effect and molecular mechanism of action of larazotide acetate in pre-clinical models via myosin light chain (MLC) phosphoryla...

Innovate Biopharmaceuticals (NASDAQ: INNT ) is 3.8% lower postmarket on solid volume after a filing by shareholders to offer 15.1M shares . More news on: Innovate Biopharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Noteworthy events during the week of May 12 - 18 for healthcare investors. More news on: Johnson & Johnson, Insmed Incorporated, Innovate Biopharmaceuticals, Inc., Healthcare stocks news, , Read more ...